BMC Cancer (Sep 2012)

CHD1L Protein is overexpressed in human ovarian carcinomas and is a novel predictive biomarker for patients survival

  • He Wei-Peng,
  • Zhou Juan,
  • Cai Mu-Yan,
  • Xiao Xiang-Shen,
  • Liao Yi-Ji,
  • Kung Hsiang-Fu,
  • Guan Xin-Yuan,
  • Xie Dan,
  • Yang Guo-Fen

DOI
https://doi.org/10.1186/1471-2407-12-437
Journal volume & issue
Vol. 12, no. 1
p. 437

Abstract

Read online

Abstract Background Our recent studies suggested that the chromodomain helicase DNA binding protein 1-like (CHD1L) gene plays an oncogenic role in human hepatocellular carcinoma. However, the status of CHD1L protein expression in ovarian cancer and its clinical/prognostic significance are obscure. Methods In this study, immunohistochemistry (IHC) for CHD1L was performed on a tissue microarray (TMA) containing 102 primary ovarian carcinomas and 44 metastatic lesions (omental metastasis). Receiver-operator curve (ROC) analysis was used to evaluate patients’ survival status. Results There is an augmented tendency of CHD1L expression in ovarian carcinoma metastasis than in primary lesions (PP PP Conclusions These findings provide evidence that positive expression of CHD1L protein is significantly correlated with the metastasis proceeding of ovarian carcinoma, and CHD1L protein expression, as examined by IHC, may act as a novel prognostic biomarker for patients with ovarian carcinoma.